Top Injectable Manufacturer in Paraguay – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 days ago
- 12 min read
Last Updated: August 23, 2026
TL;DR: Paraguay is the market where the second GMP certificate decides everything. Its regulator, the Dirección Nacional de Vigilancia Sanitaria (DINAVISA), is not a department of the health ministry but an autarkic public-law entity constituted by Ley N° 6788 of 23 August 2021 and expanded by Ley N° 7361 of 2024. Under Ley N° 3283/2007 as amended by Ley N° 7256/2024, DINAVISA publishes an annual reference-country list — Resolución DINAVISA N° 182/2026 for this year — and India is not on it. A manufacturer from a non-reference, non-MERCOSUR country must present both a GMP certificate from its own regulator and a GMP certificate issued by a reference-country authority, by MERCOSUR, or by DINAVISA itself following a foreign-plant inspection; ISO and other private-body certificates are expressly rejected. Registration is filed through the DINAVISApy platform in DINAVISA's own national format rather than eCTD, with essential medicines routed through the abbreviated procedure under Resolución N° 148/2025. Stability must be Climate Zone IVa. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines, exporting to 30+ countries, and supplying CTD/ACTD-structured dossiers with ICH Q1A(R2) stability data.
Key Takeaways
The reference-country rule is the gate, and it filters out most competitors. Under Ley N° 3283/2007 as amended by Ley N° 7256/2024, DINAVISA publishes an annual list of reference countries — Resolución DINAVISA N° 182/2026 covers the EU and EEA states plus Japan, Canada, Australia, Korea, Singapore, the United States, the United Kingdom, Saudi Arabia, Chile, Cuba, Mexico, Colombia, Argentina, Brazil, Uruguay and Paraguay. India is absent. The consequence is explicit in DINAVISA's own requirements document: a manufacturer from a non-reference, non-MERCOSUR country must file both an origin-country GMP certificate and a reference-authority, MERCOSUR or DINAVISA-issued GMP certificate, and no ISO or private certificate substitutes.
Select the portfolio off the WHO Model List, not off the catalogue. Resolución DINAVISA N° 148/2025 routes essential medicines — defined by inclusion in the WHO Model List of Essential Medicines, currently the 24th list of 2025 — through the abbreviated procedure, while innovators and non-essential products go through the ordinary procedure under Resolución N° 147/2025. Injectable EML items such as antibiotics, oxytocics, anaesthetics, analgesics, antitubercular and oncology agents take the shorter route. Sequencing the first registration wave around EML injectables is the cheapest available acceleration.
Paraguay is a tablet country buying its injectables abroad. The Unión Industrial Paraguaya study for CIFARMA of September 2024 counts 29 active national pharmaceutical manufacturers as of January 2024 and reports that 100% of censused member companies make tablets, 94.4% liquids and 77.8% creams and ointments — but only 50% make injectables at all, an undifferentiated category the study never breaks down into aseptic fill-finish, lyophilisation, cytotoxic suites or pre-filled syringes. Meanwhile the social security institute has been tendering separately, and at scale, for biological, biotechnological, immunosuppressant and oncological medicines.
India holds 2.39% of a USD 462 million import market, and is losing relative ground. UN Comtrade data reported directly by Paraguay puts 2024 HS-30 pharmaceutical imports at USD 462.44 million, with India at USD 11.03 million — rank 13, or 2.39%, down from 3.49% in 2022. In HS 3004 finished dosage forms, India is at USD 6.84 million of USD 239.71 million, rank 11. Germany, Argentina and Brazil hold roughly 40% of HS 30 between them, and Argentina and Brazil enjoy a structural registration advantage as reference authorities. The honest pitch is cost per vial on undifferentiated generics, backed by a reference-authority GMP certificate that neutralises the origin disadvantage.
Introduction: Why an Injectable Manufacturer in Paraguay Must Clear the Reference-Country Test
Paraguay imported USD 462.44 million of pharmaceutical products under HS 30 in 2024, of which USD 239.71 million was HS 3004 finished dosage forms — figures Paraguay reports directly to UN Comtrade, continuously since 1989, rather than mirror estimates derived from partner countries. The clinical demand behind those imports is substantial for a population of about 6.9 million. GLOBOCAN 2024 estimates 13,064 new cancer cases and 6,210 cancer deaths a year, with a five-year prevalence of 32,342. Among men, prostate cancer alone accounts for 2,103 new cases, or 32.1%, followed by lung at 625 and colorectum at 608. Among women, breast leads at 1,877 cases or 28.8%, followed by cervix uteri at 1,121 or 17.2%. Lung, breast, prostate, cervix and colorectum are the five leading causes of cancer death. One methodological caveat belongs in the open: the GLOBOCAN fact sheet notes that Paraguay has no country-specific incidence data source, so incidence is modelled from national mortality data.
The regulatory architecture is where most suppliers get Paraguay wrong. The medicines authority is the Dirección Nacional de Vigilancia Sanitaria, DINAVISA — and it is not a directorate of the Ministry of Public Health and Social Welfare. Ley N° 6788 of 23 August 2021 constituted it as an entity with its own legal personality under public law, administrative autonomy, autarky and its own patrimony, which executes the policies the ministry designs. Financial autarky took practical effect through Ley N° 7050 of 4 January 2023 and Decreto N° 8759 of 26 January 2023, and Ley N° 7361 of October 2024 amended and expanded its charter, adding food regulation to its remit. The predecessor body, created under Ley N° 1119/97, was the DNVS; that name is obsolete. Getting this right is not pedantry. To a Paraguayan importer, a supplier who still writes to the DNVS has plainly not read the law that governs their own file.
What Sets a World-Class Injectable Manufacturer in Paraguay Apart
The decisive requirement is documentary. Under Ley N° 3283/2007 as amended and expanded by Ley N° 7256/2024, DINAVISA publishes an annual reference-country list, this year Resolución DINAVISA N° 182/2026, covering the European Union and EEA states together with Japan, Canada, Australia, the Republic of Korea, Singapore, the United States, the United Kingdom, Saudi Arabia, Chile, Cuba, Mexico, Colombia, Argentina and Brazil, plus MERCOSUR partners Uruguay and Paraguay. India is not on that list, and DINAVISA's requirements document states the consequence directly: where the manufacturer's country of origin is neither a reference country nor a MERCOSUR member, the applicant must present both a valid GMP certificate from the origin-country regulator and a valid GMP certificate issued by a reference-country regulator, by MERCOSUR, or by DINAVISA itself — and ISO certificates or documents issued by private bodies do not apply. Where manufacture is split across countries, a GMP certificate is required for each participant. DINAVISA operates its own foreign-plant inspection route for exactly this situation. In practice an Indian sterile line already certified by EU authorities, the UK MHRA, the US FDA, ANVISA or ANMAT clears the gate immediately; a line holding only a national WHO-GMP certificate must fund and schedule an inspection.
Everything else follows from reading DINAVISA's own instructions rather than a generic Latin America template. Submission is electronic through the DINAVISApy platform in DINAVISA's structured national format, every document carrying the digital signature of the regente — content is CTD-like, but the format is not ICH CTD or eCTD. The procedure allows a maximum of three technical evaluations, and failure to resolve observations by the third means the application is denied; the applicant has 90 working days from notification to respond, extendable once by up to 60 working days on justified written request. An imported product needs a valid free-sale certificate or equivalent from the origin-country regulator, a local establishment registration and a good storage and distribution practices certificate held by the importer, a power of representation from the product owner, a trademark title in Class 5, and a good pharmacovigilance practices certificate. Foreign documents are apostilled or legalised, and powers of attorney, contracts and the free-sale certificate must be translated by a sworn public translator. Labels, cartons and leaflets are entirely in Spanish. Paraguay is not a PIC/S participating authority — within Latin America only Argentina, Brazil and Mexico are — and it is not a PAHO regional reference authority. Claims to the contrary, which circulate widely, are simply false.
Quality Systems Behind Every Batch We Ship to Paraguay
Everything leaves the Gujarat site through an ISO Class 5 aseptic core, with Grade A filling under Grade B background, routine media fills to qualify the aseptic process, and continuous viable and non-viable environmental monitoring. Each batch is released against sterility testing by the pharmacopoeial method, bacterial endotoxin testing by LAL, Karl Fischer determination of residual moisture on lyophilised presentations, HPLC and GC for assay, related substances and residual solvents, sub-visible and visible particulate matter, and container closure integrity. That is not incidental for a Paraguayan file: DINAVISA's requirements specify that the certificate of analysis and the stability protocol must include sterility and bacterial endotoxins for products classified as sterile. Analysis is written to USP, BP, IP or EP monographs according to the buyer's reference standard, and every batch ships with its certificate of analysis against retained samples.
Stability is the detail most first submissions get wrong, and it is cheap to get right. Resolución DINAVISA N° 344/2024 places Paraguay in Climate Zone IVa — hot and humid, 30 degrees Celsius and 65% relative humidity. Zone IVa long-term data at 30/65 with accelerated data at 40/75 supports a store-below-30-degrees statement; Zone II data at 25/60 are accepted only under defined conditions and force a store-below-25-degrees label, a genuine handicap in a distribution chain that runs hot. Three batches are required, pilot or industrial, and refrigerated products need long-term data at 5 plus or minus 3 degrees with accelerated data at 25/60 to six months. Artwork is the second avoidable rework: Resolución S.G. N° 046/2016 sets mandatory primary-label colours for small-volume parenterals and anaesthesia agents — blue for 0.9% sodium chloride, violet for 5% dextrose, red for potassium chloride, orange for water for injection, brown for magnesium sulfate, green for calcium gluconate and for peripheral muscle relaxants, yellow for intravenous hypnotics, orange for reversal agents, black for analgesics, white for atropine. We commit to Zone IVa data and Paraguay-specific artwork before the first submission, because both are pure rework avoidance.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Paraguay for Global Buyers
The commercial opening is precise, and it is worth stating precisely rather than overstating it. Paraguay has a genuinely substantial domestic pharmaceutical industry: 29 active national manufacturers as of January 2024, national laboratories holding an average 54% of retail market value over five years and 57% in 2024, 66% of the 87.4 million units sold in 2023, sector exports above USD 73 million in 2023 and roughly 7,000 direct employees. But the same industry study shows the capability is solid-dose dominant — 100% of censused member companies make tablets against 50% making injectables, a category the study never disaggregates into aseptic fill-finish, terminal sterilisation, lyophilisation, cytotoxic suites, pre-filled syringes or biotech capability. Nothing published establishes local capability in those complex sterile categories, and we are not going to claim the reverse either. The right positioning is against the gap, not against the local industry: a Paraguayan distributor already sells domestic orals and is looking for the parenteral half of the basket.
Public procurement is the route, and it is explicitly open to foreign bidders. Ley N° 7021/2022 on public supply and contracting, regulated by Decreto N° 9823/2023 and administered by the Dirección Nacional de Contrataciones Públicas, expressly contemplates the oferente extranjero — the bidder domiciled outside national territory — alongside national bidders and Paraguayan branches of foreign parents. Supplier registration runs through the state suppliers' registry reorganised by Resolución DNCP N° 3801/2023, with an electronic offer module now in its second version. The Instituto de Previsión Social, the contributory social security fund with its own hospital network and its own procurement, is the single most addressable buyer for injectables: Paraguayan press reporting through 2026, citing DNCP tender identifiers, describes a critical-stock medicines tender of about 51,513 million guaraníes opened on 1 June 2026 with 29 bidders, and a separate tender for biological, biotechnological, immunosuppressant and oncological medicines of about 371,106 million guaraníes — roughly USD 59 million — with offers due in August 2026. Ministry procurement runs through its strategic health inputs directorate, which coordinates the national essential medicines list with PAHO support. Two further routes are worth knowing accurately: the PAHO Strategic Fund, where contracting is with PAHO and quality entry normally requires WHO prequalification or stringent-authority evidence; and the Global Fund, where the 2026 eligibility list for the 2026 to 2028 allocation period makes Paraguay eligible for HIV only — tuberculosis is expressly not eligible because the component received transition funding in an earlier cycle.
On duties and risk, the picture is workable but should be quoted accurately. Paraguay applies the MERCOSUR common external tariff, and for most HS 3004 lines the common and the applied national rate coincide at 7.2% or 12.6% ad valorem, with 0% on a defined set of high-cost actives including streptokinase, L-asparaginase, granisetron, exemestane and daunorubicin; a handful of lines sit on the national exceptions list at slightly lower applied rates, such as rifampicin at 6% against a common rate of 7.2%. Most blood fractions and immunoglobulins under HS 3002 enter at 0%. MERCOSUR membership matters instrumentally rather than symbolically: a MERCOSUR-issued GMP certificate satisfies DINAVISA's second-certificate requirement exactly as an EU or US certificate would, and MERCOSUR's own GMP regulation adopts the WHO technical report series standard. Paraguay is a Hague Apostille contracting party, having been an HCCH member since 2005, so certificates are apostilled rather than consularised — though the sworn-translator requirement remains. It is not on the FATF list of jurisdictions under increased monitoring. The honest negatives: Transparency International's 2025 index scores Paraguay 24 out of 100 at rank 150 of 182; the country is landlocked, with the overwhelming majority of its trade routed through the Paraguay-Paraná waterway, which has been running through a multi-year low-water cycle with draft restrictions that lengthen and complicate inbound logistics; and non-communicable diseases already account for 74.9% of deaths on 2019 data, against public health expenditure of 4.47% of GDP in 2021 with 35.94% of health spending still paid out of pocket. Plan the freight and the payment terms as carefully as the dossier.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Paraguay?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, producing more than 100 injectable presentations — ampoules, vials, lyophilised powders for reconstitution and small-volume parenteral solutions — on ISO Class 5 aseptic fill-finish lines and exporting to more than 30 countries. For Paraguay specifically, the point to settle first is the second GMP certificate. Because India is not on DINAVISA's reference-country list under Resolución N° 182/2026, a non-reference-country manufacturer must file both an origin-country GMP certificate and one issued by a reference authority, by MERCOSUR, or by DINAVISA following a foreign-plant inspection. We supply CTD- and ACTD-structured dossiers, ICH Q1A(R2) stability generated to Climate Zone IVa, a Site Master File, executed batch records and certificates of analysis to USP, BP, IP or EP monographs, and we will tell you plainly which certificates a given line holds rather than implying that WHO-GMP alone settles the question.
What does medicine registration in Paraguay actually involve?
Registration is administered by DINAVISA, an autarkic public-law entity constituted by Ley N° 6788/2021 and expanded by Ley N° 7361/2024, not a directorate of the health ministry. Filing is electronic through the DINAVISApy platform in DINAVISA's own national format rather than eCTD, with each document digitally signed by the regente. Essential medicines, defined by inclusion in the WHO Model List, go through the abbreviated procedure under Resolución N° 148/2025; innovators and non-essential products go through the ordinary procedure under Resolución N° 147/2025. You need a valid free-sale certificate or equivalent from the origin regulator, the two GMP certificates described above, a locally registered establishment with a good storage and distribution practices certificate, a power of representation, a Class 5 trademark title and a good pharmacovigilance practices certificate, with everything in Spanish. The procedure allows a maximum of three technical evaluation rounds before outright denial, and the applicant has 90 working days to answer observations, extendable once by up to 60. We do not publish a decision timeline or a fee figure, because DINAVISA does not publish either in a form we can source.
Do Indian certificates need an apostille for use in Paraguay?
Yes. Paraguay is a contracting party to the Hague Convention abolishing the requirement of legalisation for foreign public documents and has been an HCCH member since 2005, so Indian public documents are apostilled rather than sent through a consular chain. Two practical qualifications matter. First, DINAVISA additionally requires that powers of attorney, contracts and the free-sale certificate be translated by a sworn public translator, which is a separate step from the apostille and is frequently forgotten. Second, electronic documents whose validity can be verified on an official web page do not require an apostille at all. Because the procedure permits only three technical evaluation rounds before denial, document preparation — not science — is where these files most often fail.
Can Paraguayan hospitals and importers buy directly from the manufacturer?
Public procurement under Ley N° 7021/2022 and Decreto N° 9823/2023, administered by the Dirección Nacional de Contrataciones Públicas, expressly contemplates the foreign bidder alongside national bidders and Paraguayan branches of foreign parents, with registration through the state suppliers' registry reorganised by Resolución DNCP N° 3801/2023. The Instituto de Previsión Social, which runs its own hospitals and its own procurement, is the most addressable buyer for injectables and has been tendering at scale through 2026 for critical-stock medicines and for biological, biotechnological, immunosuppressant and oncological products. Ministry buying runs through its strategic health inputs directorate. That said, registration requires a locally registered establishment holding a good storage and distribution practices certificate as importer, so in practice a manufacturer works with an appointed Paraguayan partner even where the supply relationship is direct.
Which injectables does Farbe Firma supply against Paraguayan demand?
The portfolio maps onto the documented burden and onto what the local industry does not make. Against GLOBOCAN 2024's estimate of 13,064 new cancer cases and 6,210 deaths a year — prostate 2,103 in men, breast 1,877 and cervix uteri 1,121 in women, with lung, breast, prostate, cervix and colorectum leading mortality — cytotoxic injectables and supportive care such as anti-emetics and corticosteroids. Against tuberculosis at 48 new cases per 100,000 on 2022 data and general hospital infection load, antibiotic injectables. Against a maternal mortality ratio of 71.1 per 100,000 live births in 2020, oxytocics and obstetric emergency products. Against non-communicable diseases at 74.9% of all deaths and hypertension at 24.6% of adults, cardiovascular injectables. Add anaesthetics, analgesics and small-volume parenterals for surgical and emergency care. Wherever possible we prioritise items on the WHO Model List of Essential Medicines, because those qualify for the abbreviated registration procedure under Resolución N° 148/2025.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments